'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.

CONCLUSIONS: Overall in 'real life' omalizumab in children reduces asthma exacerbations and hospitalizations, improves lung function, and decreases the maintenance therapy. It is shown to be safe for up to six years of treatment in children. PMID: 30509559 [PubMed - as supplied by publisher] (Source: Allergologia et Immunopathologia)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zL5K9H